Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2014 Publisher: Ferring Pharmaceuticals Ltd., Drayton Hall, Church Road, West Drayton, UB7 7PS, United Kingdom
Lutigest is indicated for luteal support as part of an Assisted Reproductive Technology (ART) treatment program for infertile women.
The dose of Lutigest is 100 mg administered vaginally three times daily starting at oocyte retrieval. The administration of Lutigest should be continued for 30 days, if pregnancy has been confirmed.
There is no relevant use of Lutinus in the paediatric population.
No clinical data have been collected in patients over age 65.
There is no experience with use of Lutigest in patients with impaired liver or renal function.
Lutigest is to be placed directly into the vagina by the applicator provided.
High doses of progesterone may cause drowsiness.
Treatment of overdosage consists of discontinuation of Lutigest together with institution of appropriate symptomatic and supportive care.
3 years.
Store in the original container in order to protect from light.
This medicinal product does not require any special temperature storage conditions.
Alu/Alu blisters of 3 vaginal tablets.
The blisters are available in cartons with 21 or 90 vaginal tablets with 1 vaginal applicator.
Not all pack sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
